Spectroscopic Analyzer Wavelength Selection for Drug Verification

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Spectroscopic analyzers, such as spectrophotometers, often provide inaccurate analysis when discriminating between different substances, making it difficult to verify or identify drugs and other substances accurately.

Innovation Solution

The use of a spectroscopic analyzer that employs a plurality of electromagnetic radiation beams with different wavelengths, specifically within the 1300nm to 2000nm range, to capture spectral characteristics of a liquid sample, combined with a processor that removes dark current components and uses reference information to identify or verify the drug sample.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional spectroscopic analysis methods are used, then the analysis process is simple, but the measurement precision and reliability of substance discrimination are poor

Engineering Contradiction:
Improvesubstance discrimination accuracyVSAvoidspectroscopic analyser complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The spectrum range (1300nm-2000nm) is segmented into multiple discrete wavelength regions, with specific wavelengths selected to target different spectral characteristics of the liquid spectrum. This segmentation allows focused measurement at critical wavelengths rather than continuous spectrum analysis, improving discrimination accuracy while managing system complexity.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the measurement parameter from broad spectrum analysis to specific wavelength selection within the 1300nm-2000nm range. By selecting wavelengths that correspond to specific spectral characteristics (peaks, troughs, inflections), the system achieves better substance discrimination through parameter optimization rather than increased complexity.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If multiple wavelengths are used to capture spectral characteristics, then the drug identification accuracy is improved, but the device complexity and cost increase

Engineering Contradiction:
Improvedrug verification reliabilityVSAvoidmulti-wavelength system complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The invention adds the wavelength dimension within the 1300nm-2000nm range, selecting specific wavelengths that correspond to different spectral characteristics. This dimensional approach allows capturing multiple spectral features (peaks, troughs, inflections) simultaneously, improving drug verification reliability without requiring complex multi-dimensional analysis systems.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The processor acts as an intermediary that receives signals from multiple wavelength detectors and processes them to identify spectral characteristics. By using the processor to analyze and correlate signals from selected wavelengths, the system achieves reliable drug verification while managing the complexity of multi-wavelength measurement through centralized signal processing.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Measurement precision

If the spectrum range 1300nm-2000nm is used to capture spectral characteristics, then the analysis accuracy is improved, but the loss of information from other spectral regions occurs

Engineering Contradiction:
Improvespectral characteristic detection precisionVSAvoidspectral information loss
Core Design Contradiction:
Measurement precisionVSLoss of information

Solution Approach 1:

The invention applies local quality by focusing measurement resources on the specific 1300nm-2000nm wavelength range where liquid spectral characteristics are most pronounced. Rather than uniformly analyzing the entire spectrum, the system concentrates measurement precision on this critical region, capturing essential spectral information (peaks, troughs, inflections) while accepting limited information from other regions.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The system performs partial action by measuring only specific wavelengths within the 1300nm-2000nm range rather than the complete spectrum. This partial measurement approach is sufficient to capture the essential spectral characteristics needed for liquid identification, achieving adequate information acquisition without the complexity of full-spectrum analysis.

Inventive Principle:
Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the accuracy of drug identification and verification by utilizing multiple wavelengths to capture specific spectral characteristics, reducing errors and improving the reliability of the analysis process.

Implementation Method 1

by directing incident radiation towards a sample, and analysing the spectral nature of the affected radiation

Methodology Applied
Scientific EffectAbsorption Spectroscopy: Absorption Spectroscopy

Implementation Method 2

a modulator is used for modulating the electromagnetic radiation beam(s) emitted at the sample resulting in detected affected radiation detected by the sample detector that is modulated

Methodology Applied
Scientific EffectModulation: Phase Modulation

Implementation Method 3

the processor removes the dark current component by multiplying the output representing the detected affected modulated electromagnetic radiation by sine and cosine functions and integrating over the period of modulation oscillation

Methodology Applied
Scientific EffectFourier Transform:

Data Source

PatentEP2694933B1Spectroscopic analyser
Publication Date: 2019.08.28 KLEIN MEDICAL
  • EP2694933B1 patent drawingFigure 1
  • EP2694933B1 patent drawingFigure 2
  • EP2694933B1 patent drawingFigure 3

AI summary

An analyser (10) for identifying or verifying or otherwise characterising a liquid based drug sample (16) comprising: an electromagnetic radiation source (11) for emitting electromagnetic radiation (14a) in at least one beam at a sample (16), the electromagnetic radiation comprising at least two different wavelengths, a sample detector (17) that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the sample, and a processor (18) for identifying or verifying the sample from the detected affected electromagnetic radiation, wherein each wavelength or at least two of the wavelengths is between substantially 1300nm and 2000nm, and each wavelength or at least two of the wavelengths is in the vicinity of the wavelength(s) of (or within a region spanning) a spectral characteristic in the liquid spectrum between substantially 1300nm and 2000nm.